Gibson Christopher 4

What Happened
Christopher Gibson, a director of Recursion Pharmaceuticals (RXRX), disposed of 40,000 shares on June 5, 2026. The shares were converted automatically from Class B common stock into Class A common stock (no cash paid on conversion) and then sold in the open market at $3.62 per share for proceeds of $144,800.

Key Details

• Transaction date: June 5, 2026. Sale price: $3.62 per share; total proceeds: $144,800.
• Conversion: 40,000 Class B shares converted into 40,000 Class A shares (automatic conversion in connection with the sale). Each Class B converts 1:1 to Class A.
• The sale was executed pursuant to a Rule 10b5‑1 trading plan (adopted May 12, 2025).
• The filing does not state Gibson’s total shares owned after this transaction in the provided excerpt.
• No indication in this report that the Form 4 was filed late.

Context
This was effectively a conversion-plus-sale (the converted shares were immediately sold), not a new cash purchase — a routine liquidity event rather than a clear bullish purchase signal. Conversions of Class B to Class A are mechanical (each Class B is convertible into one Class A) and the sale under a 10b5‑1 plan indicates pre‑scheduled trading.